Infiltrating CD4 and CD8 lymphocytes in HPV infected uterine cervical milieu

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2129425651787
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. GLOBOCAN 2012 v1.0; 2013 Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 729, 2019.
   Google Scholar
• Miller AB, ed. Epidemiologic Studies in Cancer Prevention and Screening. New York: Springer Science & Business Media; 2012.
   Google Scholar
• Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev. 2011;20(2):287–296. doi:10.1158/1055-9965.EPI-10-079121300618
   PubMed Web of Science ®Google Scholar
• Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO/IARC information centre on HPV and cancer (HPV information Centre). Human Papollomavirus and related diseases in Nepal. Summary Report 17 June 2019 Available from: https://hpvcentre.net/statistics/reports/NPL.pdf. Accessed August 04, 2019.
   Google Scholar
• Pun CB, Pradhananga KK, Siwakoti B, Subedi K, Moore MA. Malignant neoplasm burden in Nepal - data from the seven major cancer service hospitals for 2012. Asian Pac J Cancer Prev. 2016;16:8659–8663. doi:10.7314/APJCP.2015.16.18.8659
   Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Sheu BC, Chang WC, Lin HH, Chow SN, Huang SC. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia. J Obstet Gynaecol Res. 2007;33:103–113. doi:10.1111/j.1447-0756.2007.00492.x17441881
   PubMed Web of Science ®Google Scholar
• Guzm an-Olea E, Bermu dez-Morales VH, Peralta-Zaragoza O, Torres-Poveda K, Madrid-Marina V. Molecular mechanism and potential targets for blocking HPV- induced lesion development. J Oncol. 2012;20:278312.
   Google Scholar
• Nguyen HH, Broker TR, Chow LT, et al. Immune responses to human papillomavirus in genital tract of women with cervical cancer. Gynecol Oncol. 2005;96(2):452–461. doi:10.1016/j.ygyno.2004.10.01915661235
   PubMed Web of Science ®Google Scholar
• Reck M, Paz-Ares L. Immunologic checkpoint blockade in lung cancer. Semin Oncol. 2015;42:402–417. doi:10.1053/j.seminoncol.2015.02.01325965358
   PubMed Web of Science ®Google Scholar
• Helissey C, Champiat S, Soria JC. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015;27:108–117. doi:10.1097/CCO.000000000000016725602683
   PubMed Web of Science ®Google Scholar
• He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 Pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep. 2015;5:13110. doi:10.1038/srep1311026279307
   PubMed Web of Science ®Google Scholar
• Domingues D, Turner A, Silva MD, et al. Immunotherapy and lung cancer: current developments and novel targeted therapies. Immunotherapy. 2014;6:1221–1235. doi:10.2217/imt.14.8225496336
   PubMed Web of Science ®Google Scholar
• Sharon E, Streicher H, Goncalves P, Chen HX. Immune checkpoint inhibitors in clinical trials. Chin J Cancer. 2014;33: 434–4. doi:10.5732/cjc.014.10122
   PubMedGoogle Scholar
• Wagner SN, Schultewolter T, Wagner C, et al. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest. 1998;78:541–550.9605179
   PubMed Web of Science ®Google Scholar
• Davoodzadeh Gholami M, Kardar GA, Saeedi Y, Heydari S, Garssen J, Falak R. Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms. Cell Immunol. 2017;322:1–14. doi:10.1016/j.cellimm.2017.10.00229079339
   PubMed Web of Science ®Google Scholar
• Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N. Cd4 and cd8 t lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018;75:689. doi:10.1007/s00018-017-2686-729032503
   PubMed Web of Science ®Google Scholar
• Niresh T, Girishma S, Muna M, et al. Burden of cervical neoplasia in mid-western rural nepal: a population-based study. J Gynecol Oncol. 2018;29(5):e64. doi:10.3802/jgo.2018.29.e6430022628
   PubMed Web of Science ®Google Scholar
• Niresh T, Muna M, Girishma S, et al. Prevalence and type-specific distribution of human papillomavirus infection among women in mid-western rural, nepal- a population-based study. BMC Infect Dis. 2018;18(1):338. doi:10.1186/s12879-018-3109-630029626
   PubMedGoogle Scholar
• World_Health_Organization. Human Papillomavirus Laboratory Manual First. Geneva: World Health Organization; 2010.
   Google Scholar
• Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-part B: biological agents. Lancet Oncol. 2009;10:321–322. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204509700968. Accessed July 29, 2019.19350698
   PubMed Web of Science ®Google Scholar
• Hu M, Li K, Maskey N, et al. Overexpression of the chemokine receptor CXCR3 and its correlation with favorable prognosis in gastric cancer. Hum Pathol. 2015;46(12):1872–1880. doi:10.1016/j.humpath.2015.08.00426434630
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111. doi:10.1038/3507412211323675
   PubMed Web of Science ®Google Scholar
• Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25. doi:10.1016/j.coi.2014.01.00424531241
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–1570. doi:10.1126/science.120348621436444
   PubMed Web of Science ®Google Scholar
• Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–907. doi:10.1038/nature0630918026089
   PubMed Web of Science ®Google Scholar
• Verdegaal EM, de Miranda NF, Visser M, et al. Neoantigen landscape dynamics during human melanoma–T cell interactions. Nature. 2016;536:91–95. doi:10.1038/nature1894527350335
   PubMed Web of Science ®Google Scholar
• Das D, Sarkar B, Mukhopadhyay S, Banerjee C, Biswas SM. An altered ratio of cd4+ and cd8+ t lymphocytes in cervical cancer tissues and peripheral blood – a prognostic clue? Asian Pac J Cancer Prev. 2018;19(2):471.29480666
   PubMedGoogle Scholar
• Ghosh AK, Moore M. Tumour-infiltrating lymphocytes in cervical carcinoma. Eur J Cancer. 1992;28(11):1910–1916. doi:10.1016/0959-8049(92)90034-Y
   Google Scholar
• Prayitno A, Asnar E, Astirin OP, Putra ST. The expression of CD8+ and MHC-I in cervical cancer with HPV infection. J Cancer Ther. 2013;4:15–18. doi:10.4236/jct.2013.46A200325621179
   PubMedGoogle Scholar
• Carrero Y, Callejas D, Alaña F, Silva C, Mindiola R, Mosquera J. Increased vascular endothelial growth factor expression, CD3‐positive cell infiltration, and oxidative stress in premalignant lesions of the cervix. Cancer. 2009;115:3680–3688. doi:10.1002/cncr.v115:1619479977
   PubMed Web of Science ®Google Scholar
• Bedoya AM, Jaramillo R, Baena A, et al. Location and density of immune cells in precursor lesions and cervical cancer. Cancer Microenviron. 2013;6(1):69–77. doi:10.1007/s12307-012-0097-822290207
   PubMedGoogle Scholar